Table 3.

Impact of sildenafil on the risks of clinical outcomes in patients with idiopathic pulmonary fibrosis under antifibrotic treatment^*.

	Hazard ratio	95% confidence interval	P value
All-cause mortality	1.395	0.748–2.602	0.296
All-cause hospitalization	2.107	0.934–4.752	0.073
Respiratory-related hospitalization	2.051	0.924–4.551	0.077
Acute exacerbation	2.144	0.696–6.608	0.184

*Assessed by multivariable Cox analyses adjusted for the presence of pulmonary hypertension and Charlson comorbidity index.